key: cord-0814604-babzdkq0
authors: Tombuloglu, Huseyin; Sabit, Hussein; Al-Khallaf, Hamoud; Kabanja, Juma H.; Alsaeed, Moneerah; Al-Saleh, Najat; Al-Suhaimi, Ebtesam
title: Multiplex real-time RT-PCR method for the diagnosis of SARS-CoV-2 by targeting viral N, RdRP and human RP genes
date: 2022-02-18
journal: Sci Rep
DOI: 10.1038/s41598-022-06977-z
sha: 5ece95294c4ccf0c17681c2f62e2cc52eb4788cd
doc_id: 814604
cord_uid: babzdkq0

Corona Virus Disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic has brought the world to a standstill and threatened human lives. Many methods are known to date to detect this virus. Due to their relative sensitivity, polymerase chain reaction (PCR)-based assays are the most frequently applied and considered the gold standard. However, due to the rapid mutation rate of the viral genome and the emergence of new variants, existing protocols need to be updated and improved. Designing a fast and accurate PCR-based assay is of great importance for the early detection of this virus and more efficient control of the spread of this disease. This study describes a fast, reliable, easy-to-use, and high-throughput multiplex SARS-CoV-2 RT-PCR detection method. The assay was designed to detect two viral genes (N and RdRP) and a human gene (RP) simultaneously. The performance and the sensitivity of the assay were tested in 28 SARS-CoV-2 positive samples and compared with commercial kits, which showed 100% positive percent agreement with a limit of detection (LOD) value of 1.40 and 0.81 copies/µL or 35.13 and 20.31 copies/reaction for RdRP and N genes, respectively. The current assay is found accurate, reliable, simple, sensitive, and specific. It can be used as an optimized SARS-CoV-2 diagnostic assay in hospitals, medical centers, and diagnostic laboratories as well as for research purposes.

www.nature.com/scientificreports/ On the other hand, the reverse transcription polymerase chain reaction (RT-PCR) is the most common and accepted as the gold standard method for the viral detection 9 . Although RT-PCR is a standard assay, it might produce false-negative and false-positive results due to lack of specificity and sensitivity [9] [10] [11] . According to Fang et al. 12 , RT-PCR was able to detect only 71% (36/51) of SARS-CoV-2 infections. This may be due to the low sensitivity of the test, low patient viral load, or inappropriate clinical sampling 12 . The probability of obtaining a true positive result decreases with time from symptom onset. Nasopharyngeal and oropharyngeal RT-PCR tests performed on the 10th day of the first symptom have a 25% and 47% chance of being false-negative, respectively 13 . Reports showed that patients with negative initial tests became positive after 3-5 repeated swabs 14 . The rate of false-negative result changes in between 1 and 30% 15 . Therefore, the sensitivity of this method should be improved. For this purpose, multiplex PCR protocol is proposed that targets multiple genes in the same reaction. By doing so, at least two viral genes are targeted that help to increase the probability to catch the virus especially in the patients having low viral load. In addition, a human housekeeping gene can be added as an internal control to prevent false-negative results that are due to inefficient sampling.

The genome of SARS-CoV-2 contains 14 ORFs encoding for 27 proteins 16 . The genome of this virus is composed of four major structural genes that are translated to spike protein (S), small envelope protein (E), matrix protein (M), and nucleocapsid protein (N) 16 , along with some accessory genes. The surface glycoproteins (S1 and S2) are responsible for binding to the ACE2 (Angiotensin-converting enzyme 2) receptors on the host cell allowing the virus to invade, where S1 bind to the ACE2 receptor and S2 fuses with the host cell membrane 17, 18 . In addition, the genome harbors genes encoding non-structural proteins (Nsp) such as RdRP (Nsp12), the RNAdependent RNA polymerase enzyme responsible for the replication of the viral genome 19, 20 .

RT-PCR tests have been developed to target RdRP, E, N, or S genes 10, 21, 22 . Among these, those targeting RdRP gene were found to be the ones with the highest analytical sensitivity 9, 23 . In addition, the human ribonuclease P (RNase P or RP) gene (responsible for the processing of tRNA molecules) is used as an internal control in multiplex RT-PCR protocols recommended by WHO and CDC [24] [25] [26] . There is also a need for studies to compare between recently developed assays based on their reproducibility, and sensitivity. Therefore, in addition to the experimental design, determining which genes to be targeted by the assay, are also extremely important goals to achieve when designing molecular testing protocols. Although multiplex RT-PCR method helps to improve the specificity, the design of multiplex primers and probe sets is very critical for the PCR efficiency. The formation of self-dimer or hetero-dimer structure reduce the target specificity and may lead to misinterpretation of the results. Therefore, the experimental design as well as the selection of the best primer and probe sets are crucial and needs standardization. Together with, real-time RT-PCR results may be affected by variations in viral RNA sequences 27 . A recent study estimated the nucleotide mutation rate of the SARS-CoV-2 genome as 6.677 × 10 −4 substitution per site per year 28 , which lead loss of the assay sensitivity as shown by Peñarrubia et al. 29 . The emergence of new variants and the high mutation rate of the viral genome require updating existing diagnostic tests.

In this study, a multiplex real time RT-PCR (rRT-PCR) assay was designed and evaluated for the diagnosis of SARS-CoV-2 including the most recent variant of concerns (VOC). The study exhibits primer sets specific to SARS-CoV-2 and the accompanying optimized reaction conditions. The developed assay simultaneously detects viral N, RdRP and human RP genes in the same rRT-PCR reaction. The clinical performance of the test was screened with RNA samples from SARS-CoV-2 positive patients.

SARS-CoV-2 genome sequences. In total, 344 SARS-CoV-2 genomes belongs to variants of concern (VOC) including alpha (B.1.1.7), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) were analyzed. The sequences were retrieved from GISAID database 30 and chosen by covering all continents including Europa, North and South America, Asia, Africa, and Oceania. The sequences were aligned by using MAFFT software (https:// mafft. cbrc. jp/ align ment/ server/) with default settings 31 . Then, the interested genome regions harboring the primer target sites for N and RdRP genes were selected and a possible substitution or single nucleotide polymorphism at the primer binding sites were screened by using JalView (v2.11.1.3) program 32 (Supplementary Figs. S4 and S5). The consensus sequences (100% alignments) corresponding to the target genes were selected for primer design. The primers were synthesized by Molequle-On (Auckland, New Zealand) and purified by highperformance liquid chromatography.

Multiplex primer/probe design. To design the most suitable multiplex primers, PrimerPooler 33 , Primer-Plex (http:// www. premi erbio soft. com/ prime rplex/ index. html) and Primer3 34 programs were used with default settings. The possible secondary structures such as homo-dimer, hetero-dimer, and hairpin were checked by using OligoAnalyzer™ Tool of Integrated DNA Technologies (IDT) (https:// eu. idtdna. com/ pages/ tools/ oligo analy zer). In the selection of SARS-CoV-2 primers, attention was paid to the selection of genome regions that differ from other SARS-CoV relatives (NC_004718.3, AY613947.1, AY502927.1, AY278491.2, AY502924.1, and AY559094.1) (Supplementary Figs. S5 and S6). Therefore, the primers are specific to SARS-CoV-2 virus only and are expected to be free from possible cross reactions with other SARS viruses. Each gene-specific probe was labeled with different fluorescent dye: fluorescein amidides (FAM) for the viral RdRp gene, hexachlorofluorescein (HEX) for the viral N gene, and carboxyrodamine (ROX) for the human RP gene. The concentration, size, and sequence of each primer or probe are indicated in Table 1 Applied Biosystems™, 7500 Fast Real-Time PCR system was used for rRT-PCR reactions. Prior to this procedure, the instrument was calibrated using the Applied Biosystems™ 7500 Rapid Real Time PCR Systems Spectral Calibration Kit. The following conditions were applied for the rRT-PCR reaction: (1) reverse transcription at 42 °C for 15 min, (2) pre-denaturation at 95 °C for 5 min. For the cyclic reactions (40×) (3) denaturation at 95 °C for 5 s and (4) amplification at 60 °C for 30 s. The fluorescence reading was performed at the amplification step. The reporter dye channel was determined as FAM for the RdRp gene, VIC for the N gene, and ROX for the RNAseP (RP) gene. For the Applied Biosystems™ real time PCR instrument (7500 and StepOne models), "passive reference" is set to "none".

Amplification efficiency and analytical sensitivity. The rRT-PCR amplification efficiency (E) was calculated for each viral gene. For this, dilution series of template RNA (Reference No: EURM-019, European Commission Joint Research Centre) was prepared and a standard curve was generated. Ct values were drawn for the logarithmic measurement of the template used. Amplification efficiency was calculated according to the following formula:

The RNA concentration was determined by Nanodrop 2000 (Thermo Fisher Scientific, USA) and the copy number was determined according to the following formula 35, 36 :

Multiple units are used to display limit-of-detection (LOD), for example viral genomic RNA copies per milliliter of transfer medium (copies/mL), copies/µL, copies per reaction volume, or molarity of the test target, etc., which are sometimes confused 37 . To demonstrate the sensitivity of current assay, the LOD number was calculated and expressed in two different units: (1) the number of copies in one µL of the reaction mixture (copies/µL) and (2) the number of copies in the reaction (copies/reaction). For this, serial dilution of synthetic RNA (5 × 10 4 , 5 × 10 3 , 5 × 10 2 , 5 × 10 1 , and 5 × 10 0 copies/µL) was prepared. Since 5 µL of template solution was used in the PCR reaction, the lowest dilution (5 × 10 0 copies/µL) contains 25 copies of RNA. In total, 25 copies of RNA in 20 µL of reaction mixture corresponds to 1.25 copies/µL or 25 copies/reaction. In addition, the probit regression analysis was performed by using MedCalc program (version 19.2; MedCalc Software, Ostend, Belgium).

(2) RNA copies/mL = RNA concentration g/mL / nt transcript length × 340 ×6.022×10 23 . Ethical approval. The study is approved by the Institutional Review Board (IRB) at Imam Abdulrahman bin Faisal University (IAU) with an IRB number of IRB-2020-13-406. All methods were carried out in accordance with relevant guidelines and regulations. The de-identified samples left over after completion of diagnostic tests were used; hence this study requires no consenting as per institutional ethics committee regulations and informed consent.

Standardization of the multiplex rRT-PCR. A multiplex rRT-PCR assay was optimized for the diagnosis of SARS-CoV-2. The assay simultaneously targets two viral genes (RdRP and N) and one human gene (RP) as internal control (Fig. 1) . The assay tested in 28 RNA samples collected from COVID-19 positive individuals. Supplementary Figure S1 exhibits the rRT-PCR outputs belonging to COVID-19 positive and negative individuals. In COVID-19 positive samples, the RP, RdRP, and N genes amplified simultaneously, forming S-shaped sigmoidal curves (Supplementary Fig. S1a ). In the COVID-19 negative specimen, the internal control gene (RP) was the only gene amplified with a sigmoidal amplification curve ( Supplementary Fig. S1b ). In the positive control reactions, pseudoviral RNA including N and RdRP regions and a human RP mRNA was used as template.

The amplification curves were obtained for all targeted genes ( Supplementary Fig. S1c ). In the negative control reactions, ddH 2 O was used as the template, which led no amplification line without primer dimer formation (homo-dimer or hetero-dimer). The results showed that the multiplex primer and probe design successfully amplify all targeted genes both in SARS-CoV-2 positive specimen and synthetic positive control samples without forming primer dimer or self-amplification. In addition, the standard curve analysis was performed to test the sensitivity of the assay. For this purpose, a dilution series of clinical RNA was prepared with a dilution factor range of 10 5 to 10 1 (Fig. 2; Supplementary  Fig. S2 ). Triplicate rRT-PCR analysis revealed that the results are consistent across technical replicates. The test ran successfully even on samples diluted 10 5 times. The rRT-PCR efficiency for both RdRP and N genes is 99.7 and the R 2 value is > 0.997, which shows the consistency and reliability of the assay. Table S1 ). Accordingly, the Ct value equals and lower than 37 is accepted as positive. Besides, in both assays, the Ct score of those negative samples was higher than 37, which is out of the CDC and WHO recommendations 38, 39 . Therefore, the samples having a Ct score of ≥ 37.01 are accepted as SARS-CoV-2 negative. In this case, the assay exhibited 100% positive percent agreement with those commercial assays. The distribution of Ct value obtained from both commercial methods and this mCoV-2 assay are displayed in Fig. 3 . Since these kits target different genes, the Ct scores of those genes were combined. Accordingly, it is obvious that the average Ct value of the current assay is lower than those of the genes targeted in the comparative commercial kits. This result demonstrates the high sensitivity of the current assay.

A serial dilution of synthetic RNA (5 × 10 4 , 5 × 10 3 , 5 × 10 2 , 5 × 10 1 , and 5 × 10 0 copies/µL) was prepared to find out the limit-of-detection (LOD) for RdRP and N genes. The amplification plots, the amplification efficiencies (E), and R 2 score are represented in Fig. 4 . The probit regression analysis of the serially diluted synthetic RNAs (at least 10 replicates) determined the LOD of N gene as 0.81 copy/µL or 20.31 copy/reaction (Fig. 4e) . Together with, the LOD of RdRP gene was computed as 1.40 copy/ 

Since rRT-PCR method is considered the gold standard in the diagnosis of SARS-CoV-2, WHO and CDC recommend it as the diagnostic test for asymptomatic and mildly symptomatic patients 6, 40 . However, rRT-PCR methods also have some drawbacks such as possible false-negative or false-positive results, the cost, etc 41 . In order to eliminate or minimize those drawbacks, multiplex rRT-PCR methods have been developed that target more than one gene at the same time. By doing this, it is aimed to improve rRT-PCR efficiency and sensitivity. Until now, many studies have been conducted to find the method that can detect the SARS-CoV-2 RNA with the highest sensitivity. For this, different combinations of targeted viral genes were tested in multiplex. According to the WHO recommendations, four viral genes (RdRp, E, N and S genes) can be used in multiplex rRT-PCR reactions in different combinations 42 . Along with these genes, primer and probe sequences of the human internal/positive control RNase P (RP) gene have been published and their use has been recommended by US CDC 24 . The studies to improve these protocols are still ongoing. Designing primers with the highest sensitivity towards the target gene, eliminating their cross reactivity, minimizing possible false negative and positive results, 43 demonstrated a faulty design in RP primer sets defined by the CDC, which is another example of the importance of those improvement studies. Together with, it has been shown by many studies that the SARS-CoV-2 genome evolve very fast as a consequence of the lack of proofreading activity of polymerases 29, 44 . In a recent study, the nucleotide mutation rate of the SARS-CoV-2 genome was found as 6.677 × 10 −4 substitution per site per year 28 . Due to the high susceptibility to mutation, it has been shown that more than one variant can be present in a patient at the same time 45 . For instance, a meta-transcriptome analyses of 110 SARS-CoV-2 sequences obtained from BAF samples (Bronchoalveolar fluid) from eight patients revealed the evolution of SARS-CoV-2 in the patient and that many variants can be found simultaneously in the individual 45 . Emergence of variations by new mutations, in particular when they placed on the RT-PCR primer binding sites, and active viral recombination 46 can cause loss of the assay sensitivity 29 and false-negative results 27 . Therefore, the selection and update of primer target regions and targeting more than one gene are of great importance. The RT-PCR protocols in particular the target regions/sequences should be updated by considering the most recent mutations and variants.

In this study, a multiplex rRT-PCR method has been developed that simultaneously targets the viral N and RdRP genes and the human RP gene. The primer and probe sets were designed to obtain the best PCR efficiency and target specificity. Due to the rapid evolution of SARS-CoV-2 genome 47 48 . On the other hand, 1% of heterogeneous sequences presented inconsistencies, particularly a mismatch between the SARS-CoV-2 genome and the commercial primer, including genes selected in WHO-recommended RT-PCR detection tests. For example, two regions of genetic variability were identified in the sequence of RdRP gene primers recommended by the US CDC 48, 49 . This variation can have a critical impact on the reliability and sensitivity of the assay.

According to the results, the rRT-PCR efficiencies of tenfold dilutions series of the standards were > 99 for both N and RdRP genes ( Fig. 2; Supplementary Fig. S2) , which matches the criteria for an efficient RT-qPCR assay 50 . Besides, the current protocol allows the diagnosis of SARS-CoV-2 RNA with a limit of detection (LOD) value of 0.81 copies/µL or 20.31 copies/reaction for the N gene, and 1.40 copies/µL or 35.13 copies/reaction for the RdRP gene (Fig. 4) . The estimated 95% confidence intervals (CI) for the LODs of N and RdRP genes are 6.95-379.25 and 12.2-640.2 copies/reaction, respectively. The corresponding copy number of each gene per µL (copies/µL) varied between 0.27 and 15.17 copies/µL for the N gene, and 0.48 and 25.60 for the RdRP gene. The LOD of the CDC's 2019-nCoV Real-Time RT-PCR Diagnostic Panel is 10 copies/μL. According to Vogels et al. 51 , all SARS-CoV-2 primer and probe sets that has capacity to detect 500 copies/reaction can be used to diagnose SARS-CoV-2. Pfefferle et al. 52 demonstrated that the LOD of RT-PCR assay was 689.3 copies/mL with 275.72 copies per reaction. In this study, GeneFinder TM COVID-19 Plus RealAmp Kit (GeneFinder, Korea) and RealStar SARS-CoV-2 RT-PCR Kit 1.0 (Altona, Germany) has been used to verify the assay control. The LOD of the GeneFinder kit is 0.5 copies/µL for both upper respiratory and sputum specimen as measured on the ABI 7500, ABI 7500 Fast, and CFX96 instruments 53 . Another study using a digital PCR (dPCR) assay found it as 0.149 and 0.163 copies/µL for N1 and N2 genes, respectively 54 . The LOD of the RealStar kit was 1.2 copies/µL in nasopharyngeal swabs (NP) specimens; but 12 copies/µL in bronchoalveolar lavage (BAL) specimens 55 . The LODs of three SARS-CoV-2 RT-PCR kits, Allplex (Seegene, Korea), PowerChek (KogeneBiotech, Korea), and Real-Q (BioSewoom, Korea), were found to be 153.94, 84.12, and 80.60 copies/reaction, respectively 56 . Overall, it can be said that the current assay has at least as high sensitivity as the recommended and known tests, or even more than some.

The validation of the assay was tested by using viral RNA samples extracted from the swabs of SARS-CoV-2 positive individuals (n = 28). It is revealed that three samples out of 28 did not match with the results of the commercial kits (Supplementary Table S1 ). In both assays, either commercial or the current one, it is estimated that the Ct score of those negative samples was higher than > 37.01 which is out of the WHO recommendation 36 . Therefore, in the current mCoV-2 assay, they are called as negative. Accordingly, the Ct value equals and lower than 37 is accepted as positive.

For COVID19, RT-PCR detection kits are commonly destined to amplify the genes S, E, N, RdRP, and ORF1a/b, but ORF1a/b and E were mostly applied 57, 58 . In China, Orf1ab and N genes are regularly used, while N1, N2 and N3 genes were utilized in US CDC and E, N, and RdRP genes in Europe 59 . The importance of N1 and N2 primer-probes is for providing a less conservative but more sensitive than the RdRP primer-probes especially in samples that have low viral titers 60, 61 . In a recent study, where swabs from confirmed cases were taken from nasopharynx and pharynx targeting ORF1ab and N genes yielded the best sensitivity when compared to positive confirmed samples 61 . Chu et al. 62 have reported two assays that had the capability to achieve a large dynamic range and recommended targeting N gene for screening and the ORF1b gene to confirm the result. Together with, a case report found that after 9 and 10 days from the onset of disease, an RT-PCR kit detected a single positive gene which is nucleocapsid (N), but not the orf1ab gene. On day 16, both genes resulted in positive amplification which suggests that the N gene is more sensitive to amplify than the orf1ab gene 63 . The abovementioned studies confirmed the capability of targeting N gene to be utilized in the detection of COVID-19 with other genes. While Li et al. 64 concluded that the more stable E gene is the target for the standardization of coronavirus tests, but N and RdRP genes are mostly targeted to confirm the results. In our study, it seems that targeting RdRP and N genes will make the test more sensitive. However, more studies are needed for fast and accurate COVID19 detection. www.nature.com/scientificreports/ Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

Covid-19 Coronavirus Pandemic

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review

Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results

Molecular and serological tests for COVID-19 a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics

What we know about the COVID-19 immune response

Laboratory Testing for 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases

Advice on the Use of Point-Of-Care Immunodiagnostic Tests for COVID-19

html#: ~: text= Autho rized% 20ass ays% 20for% 20vir al% 20tes ting,COVID% 2D19% 2C% 20is% 20pre sent

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens

Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity

Sensitivity of chest CT for COVID-19: Comparison to RT-PCR

Estimating the false-negative test probability of SARS-CoV-2 by RT-PCR

Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients

Occurrence and timing of subsequent SARS-CoV-2 RT-PCR positivity among initially negative patients

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor

Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective

Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria

Development of multiplex real-time RT-PCR assay for the detection of SARS-CoV-2

Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19

CDC. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel

Ct values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load

Development of a new multiplex real-time RT-PCR assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection

Real-time RT-PCR in COVID-19 detection: Issues affecting the results

Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States

Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak

The GISAID (Global Initiative on Sharing All Influenza Data

Multiple sequence alignment, interactive sequence choice and visualization

Jalview Version 2-A multiple sequence alignment editor and analysis workbench

Automated primer pooling to prepare library for targeted sequencing

Primer3-New capabilities and interfaces

A mismatch-tolerant RT-LAMP method for molecular diagnosis of highly variable viruses

Comparative evaluation of 19 reverse transcription loop-mediated isothermal amplification assays for detection of SARS-CoV-2

SARS-CoV2 testing: the limit of detection matters

CDC. FAQs about the CDC DENV-1-4 Real-Time RT-PCR Multiplex Assay

201005_ final_ pqpr_ eul_ 0517_ 204_ 00_ sars_ cov2_ nucle ic_ acid_ detec tion% 20% 281% 29. pdf

Testing for COVID-19

Recent advances and perspectives of nucleic acid detection for coronavirus

Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance

Overhauling a faulty control in the CDC-recommended SARS-CoV-2 RT-PCR test

Genetic diversity and evolution of SARS-CoV-2

Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with coronavirus disease 2019

novel coronavirus is undergoing active recombination

Polymorphic landscape of SARS-CoV-2 genomes isolated from Indian population in 2020 demonstrates rapid evolution in ORF3a, ORF8, nucleocapsid phosphoprotein and spike glycoprotein

Molecular analysis of several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of genetic variability of the virus in Colombia

Reliability of real-time RT-PCR tests to detect SARS-Cov-2: A literature review

How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets

Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system

GeneFinder™ COVID-19 Plus RealAmp

Digital PCR for high sensitivity viral detection in false-negative SARS-CoV-2 patients

Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays

Evaluation of four commercial kits for SARS-CoV-2 real-time reverse-transcription polymerase chain reaction approved by emergency-use-authorization in Korea

Diagnostic methods and potential portable biosensors for coronavirus disease 2019

Diagnostic techniques for COVID-19 and new developments

Landscape coronavirus disease 2019 test (COVID-19 test) in vitro-A comparison of PCR vs immunoassay vs Crispr-based test

Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation

Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative

Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia

Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient

Primer design for quantitative real-time PCR for the emerging Coronavirus SARS-CoV-2

This study is funded by Institute for Research and Medical Consultations (IRMC) under the project number 2020-IRMC-S-3 and the Deanship of Scientific Research (DSR) of Imam Abdulrahman Bin Faisal University (IAU) Fast track fund of COVID-19 (COVID19-2020-026-IRMC). We would like to thank Mr. Geoffrey James T. Moro for technical assistance in conducting RT-PCR experiments. The schema is created with BioRender.com.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-06977-z.Correspondence and requests for materials should be addressed to H.T.Reprints and permissions information is available at www.nature.com/reprints.